2024 is expected to be a stellar year in generative AI, continuing the trend from 2023. But for the majority of the legacy companies formed prior to the deep learning revolution in 2014 and ...
The next leap in oncology therapeutics demands speed, precision, and rapid molecular innovation — and AI-driven antibody design (AIDD) is beginning to deliver. In this talk, we will unveil how our ...
Viva Biotech, a company provides one-stop services ranging from early-stage structure-based drug R&D to commercial manufacturing to global biopharmaceutical innovators, successfully held the AIDD ...
In the perpetual competition for survival, both humans and bacteria are in a constant state of evolution to better suit their changing environments. Tuberculosis, a disease with roots stretching back ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...
While ChatGPT, released in 2022, brought advances in generative AI into the consumer domain, many advances in deep learning and generative AI for drug discovery were made in the past decade. My first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback